Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, exenatide (Byetta®) cannot be endorsed for use within NHS Wales as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults who have not achieved adequate glycaemic control with these agents. |
||
|
||
Medicine details |
||
| Medicine name | exenatide (Byetta®) | |
| Formulation | 5 mg and 10 mg solution for injection | |
| Reference number | 1385 | |
| Indication | Adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults who have not achieved adequate glycaemic control with these agents |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2012 | |